SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

TRUMP is drawing attention amid volatile trading and election-linked speculation: some traders tout accumulation or a possible short squeeze, while many others focus on the tokens steep decline and alleged insider cash-outs. Midterm outcomes are cited as a potential pressure point, but no confirmed new catalyst dominates the discussion.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

OXYs breakout to a six-month high amid strength in oil stocks is drawing attention, with bullish call-option activity adding to the momentum. Traders are watching for follow-through, while others question why the shares have not tracked crude prices more closely and point to resistance ahead.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owls Q3 results and upbeat earnings-call outlook are driving attention, with traders highlighting fee and AUM growth, dividend coverage, and unearned-fee backlog as reasons for optimism. Some remain cautious about private-credit redemptions and whether fee growth is durable, while bullish traders see the results as a counterpoint to lingering sector concerns.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstones reported expectation that Anthropic could receive a speculative-grade credit rating, reversing its earlier outlook, has drawn attention amid scrutiny of AI financing risk. Traders debate whether the report intensified selling, while call-heavy options activity is viewed by some as positioning rather than a clear bullish bet.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons Q3 results beat expectations, with strong refining margins and record U.S. refinery throughput driving much of the discussion despite weaker upstream performance. Traders point to bullish call-heavy options activity and new highs, while debating whether refining gains and energy-price tailwinds will last.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat is driving a sharp rally and a new 52-week high, with traders highlighting growth across Dupixent, Eylea HD and Libtayo. The reaction is broadly bullish, though some note that declining legacy Eylea sales and potential profit-taking could temper the momentum.

VXX tracks an index with exposure to futures contracts on the CBOE Volatility Index with average one-month maturity. Exposure resets daily.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

A rebound in volatility has put VXX in focus as traders weigh hedging for a possible market pullback amid broader uncertainty. Some see the move as the start of a sustained volatility breakout, while others expect a short-lived pop and point to VXXs futures-related decay as a reason to fade rallies.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotify is rising after its latest quarterly report, with traders focusing less on the earnings and revenue shortfalls than on stronger subscriber additions, gross margin, and a better profit outlook for the next quarter. The move has prompted bullish breakout and options-flow chatter, alongside skepticism that the rally is justified despite the mixed results.

Pyth Network (PYTH) is a cryptocurrency launched in 2021and operates on the Solana platform. Pyth Network has a current supply of 9,999,981,857.422035 with 7,874,958,862.767691 in circulation. The last known price of Pyth Network is 0.06608465 USD and is up 1.61 over the last 24 hours. It is currently trading on 450 active market(s) with $21,484,088.50 traded over the last 24 hours. More information can be found at https://pyth.network/.

Pyth Network

Pyths Nasdaq data-distribution and broader real-world-asset push are fueling bullish discussion, alongside the DAOs policy directing product revenue toward PYTH reserve accumulation. Traders see these developments as strengthening the tokens demand story, while others point to weak price action and potential token-unlock selling pressure.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

Traders are focused on RSP as a measure and potential beneficiary of shifting market breadth, comparing its performance with cap-weighted SPY amid rotation between mega-cap tech and other S&P 500 stocks. Some view stronger equal-weight performance as healthy broadening, while others see weak breadth and failed breakouts as signs that participation remains fragile.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayPR NewswireNEW YORK, Oct. 20, 2026 NEW YORK, Oct. 20, 2026 /PRNewswire/ -- Market Updates News Commentary- Two unrelated...

Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today

Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.read more...

Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study

Disc Medicine reports positive Phase 3 results for bitopertin in EPP, meeting all primary and secondary endpoints. NDA resubmission planned.read more...

Big Money, Bold Science, and Next Wave of Biotech Catalysts

Biotechnology is delivering a fresh wave of developments that could reshape investor expectations for Disc Medicine (NASDAQ:IRON), Silence Therapeutics (NASDAQ:SLN), NeOnc Technologies Holdings (NASDAQ:NTHI), and Alaunos Therapeutics (NASDAQ:TCRT).

Futures Rise As Dip Buyers Rush Back Into Chips After Worst Nasdaq Week Since Liberation Day

Futures Rise As Dip Buyers Rush Back Into Chips After Worst Nasdaq Week Since Liberation Day

 US futures are higher - but well off session highs hit before the European open - as dip buyers storm back into chipmakers after the Nasdaq's worst week since the April 2025 tariff turmoil...

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers

Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion.
DataMEDS AI (NASDAQ:MEDS) shares moved upwards byread more...

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONPR NewswireNEW YORK, Oct. 2, 2026NEW YORK, Oct. 2, 2026...

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONPR NewswireNEW YORK, Sept. 21, 2026 NEW YORK, Sept. 21, 2026...

Rosen Law Firm Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - IRON Rosen Law Firm Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - IRONPR...

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONPR NewswireNEW YORK, Sept. 11, 2026 NEW YORK, Sept. 11, 2026...

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The agency said that the company must provide evidence of clinical benefit from “adequate and well-controlled trial(s)” for approval.</li><li>Disc Medicine’s bitopertin is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program.&nbsp;</li><li>Disc said it would resubmit its application following the completion of its APOLLO trial and expects a fresh decision from the agency by mid-2027.</li></ul>Shares of Disc Medicine (IRON) slumped 21% on Friday after the U.S. Food and Drug Administration refused to approve the company’s bitopertin oral tablets for the treatment of Erythropoietic Protoporphyria.Disc Medicine’s Bitopertin is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program announced in June 2025. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.<h2 class="st-heading-2">FDA’s Rationale</h2>The FDA said in a letter to the company published on Friday that the data submitted by the company is insufficient proof of clinical benefit. The agency said that the company must now provide evidence of clinical benefit from “adequate and well-controlled trial(s)” for approval.The agency also expressed willingness to meet with the company to discuss options including the completion of an ongoing late-stage trial called Apollo and using it to seek a traditional approval.Disc Medicine was seeking approval of the pill in Erythropoietic Protoporphyria, a rare, inherited metabolic disorder causing extreme sensitivity to sunlight and artificial light, leading to immediate, painful skin reactions like burning, redness, and swelling.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-receives-complete-response-letter-fda-bitopertin">confirmed</a> the receipt of the letter and said that it expects to seek a meeting with the agency.“The CRL will delay the potential approval of bitopertin, but we have confidence in the ongoing APOLLO trial…,” CEO John Quisel said. The company also added that the issues raised by the FDA in the letter are “readily addressable” with data from its APOLLO trial expected in the fourth quarter (Q4).The company said it would resubmit its application following the completion of the APOLLO trial and expects a fresh decision from the agency by mid-2027.Last month, Reuters reported that the FDA has delayed the review of bitopertin after its scientists flagged safety and efficacy concerns. The decision was previously slated for January-end but pushed back two weeks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IRON stock jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user now expects the FDA to decide on an approval for the pills only by late 2027. “Debating whether to start a small position now or wait for further downside,” they wrote.<stembedurl>https://www.stocktwits.com/jamonda/message/644968897</stembedurl><a href="https://stocktwits.com/symbol/IRON">IRON stock</a> has gained 5% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-to-cease-one-time-sale-of-fsd-starting-sunday/cZRdcaLR4t0">Tesla To Cease One-Time Sale Of FSD In Favor Of Subscription Model</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Disc Medicine logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The FDA said in a letter to the company published on Friday that the data submitted by the company is insufficient proof of clinical benefit for bitopertin. 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$80.84
Prev Close	$82.84
Open	$82.79
Dividend Yield	0.00%
50-Day Moving Average	$71.36
Beta	1.16
Avg. Volume	558,246.59
PE Ratio	-12.29

52-Week High	$99.50
52-Week Low	$40.00
Market Capitalization	$3.59B
EPS (Annual)	-$6.01
Price to Book	4.81
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

IRON Fundamentals